News

Vertex Pharmaceuticals Incorporated VRTX stock has declined 8.9% in the past three months. The deterioration was due to soft first-quarter results, slower-than-expected uptake of its newer drugs ...
Vertex will continue to work with reimbursement bodies across the European Union member states to ensure access for all eligible patients as quickly as possible. Story Continues and ...
Google is rolling out Veo 3 to everyone using Vertex AI, which is an ML-testing platform provided by Google Cloud. Unlike Sora and other generative video AI models, Veo 3 is a state-of-the-art ...
A finance executive overseeing the implementation of a tax solution. Vertex, Inc. (NASDAQ:VERX) is not on our list of 30 Most Popular Stocks Among Hedge Funds.
See the latest Vertex Pharmaceuticals Inc stock price (VRTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.
Vertex could be closing in on a deal with the NHS over its portfolio of cystic fibrosis drugs, after health ministers wrote to the US firm asking for a conclusion to talks after almost two years ...
Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880.
Review the current valuation for Vertex Pharmaceuticals Inc (VRTX:XNAS) stock based on a yearly calendar providing PE ratios, cash flow, EBITDA and other company valuation information.
Vertex Pharmaceuticals Share Price Live Today:Get the Live stock price of VRTX Inc., and quote, performance, latest news to help you with stock trading and investing.Check out why Vertex ...
Vertex’s CEO Reshma Kewalramani said: “Thousands of people with cystic fibrosis across the EU may now benefit from this new, once-daily medicine, which has demonstrated further improvement in CFTR ...
Vertex Pharmaceuticals (NASDAQ: VRTX) announced that the European Commission has authorized its CFTR modulator, Alyftrek (deutivacaftor), for treating individuals with cystic fibrosis.